Brokerages forecast that Agios Pharmaceuticals (NASDAQ:AGIO) will announce ($1.60) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Agios Pharmaceuticals’ earnings, with estimates ranging from ($1.65) to ($1.54). Agios Pharmaceuticals posted earnings per share of ($1.56) in the same quarter last year, which would suggest a negative year over year growth rate of 2.6%. The company is scheduled to issue its next earnings report before the market opens on Thursday, May 3rd.
According to Zacks, analysts expect that Agios Pharmaceuticals will report full year earnings of ($6.25) per share for the current financial year, with EPS estimates ranging from ($6.51) to ($5.60). For the next fiscal year, analysts forecast that the business will post earnings of ($4.42) per share, with EPS estimates ranging from ($6.00) to ($0.01). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover Agios Pharmaceuticals.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.65) by ($0.16). The business had revenue of $9.80 million for the quarter, compared to the consensus estimate of $12.65 million. Agios Pharmaceuticals had a negative return on equity of 76.67% and a negative net margin of 731.60%. The business’s revenue was down 56.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.34) earnings per share.
Several research firms have weighed in on AGIO. Credit Suisse Group set a $95.00 target price on Agios Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday. ValuEngine raised Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. UBS downgraded Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 14th. JPMorgan Chase lifted their price target on Agios Pharmaceuticals from $76.00 to $85.00 and gave the company an “overweight” rating in a research note on Thursday, February 15th. Finally, Oppenheimer downgraded Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 14th. They noted that the move was a valuation call. Three equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $87.00.
AGIO stock traded down $0.15 during midday trading on Thursday, hitting $87.33. 428,792 shares of the company’s stock were exchanged, compared to its average volume of 432,625. The firm has a market cap of $5,014.94, a PE ratio of -12.94 and a beta of 1.98. Agios Pharmaceuticals has a one year low of $45.11 and a one year high of $89.33.
In other Agios Pharmaceuticals news, insider Steven L. Hoerter sold 25,000 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $74.83, for a total value of $1,870,750.00. Following the sale, the insider now owns 25,000 shares of the company’s stock, valued at approximately $1,870,750. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Christopher Bowden sold 2,000 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.75, for a total value of $157,500.00. Following the completion of the sale, the insider now directly owns 2,881 shares in the company, valued at approximately $226,878.75. The disclosure for this sale can be found here. Insiders sold a total of 210,880 shares of company stock worth $16,368,948 in the last three months. Company insiders own 5.43% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Agios Pharmaceuticals by 41.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,600 shares of the biopharmaceutical company’s stock valued at $149,000 after acquiring an additional 762 shares during the last quarter. California Public Employees Retirement System increased its position in shares of Agios Pharmaceuticals by 3.4% in the third quarter. California Public Employees Retirement System now owns 36,100 shares of the biopharmaceutical company’s stock valued at $2,410,000 after acquiring an additional 1,200 shares during the last quarter. Bank of Montreal Can increased its position in shares of Agios Pharmaceuticals by 74.8% in the fourth quarter. Bank of Montreal Can now owns 3,551 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 1,520 shares during the last quarter. Swiss National Bank increased its position in shares of Agios Pharmaceuticals by 2.3% in the fourth quarter. Swiss National Bank now owns 70,060 shares of the biopharmaceutical company’s stock valued at $4,005,000 after acquiring an additional 1,600 shares during the last quarter. Finally, Nationwide Fund Advisors increased its position in shares of Agios Pharmaceuticals by 37.8% in the third quarter. Nationwide Fund Advisors now owns 6,344 shares of the biopharmaceutical company’s stock valued at $423,000 after acquiring an additional 1,740 shares during the last quarter. 82.41% of the stock is currently owned by institutional investors and hedge funds.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.